Aperio Group LLC Has $5.57 Million Position in Incyte Co. (INCY)
Aperio Group LLC raised its holdings in shares of Incyte Co. (NASDAQ:INCY) by 12.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 58,772 shares of the biopharmaceutical company’s stock after acquiring an additional 6,322 shares during the quarter. Aperio Group LLC’s holdings in Incyte were worth $5,566,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in INCY. Ark Investment Management LLC boosted its position in shares of Incyte by 171.2% during the 2nd quarter. Ark Investment Management LLC now owns 3,911 shares of the biopharmaceutical company’s stock worth $492,000 after acquiring an additional 2,469 shares in the last quarter. AHL Partners LLP acquired a new position in shares of Incyte during the 2nd quarter worth about $556,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Incyte during the 2nd quarter worth about $2,292,000. Ameritas Investment Partners Inc. boosted its position in shares of Incyte by 1.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,571 shares of the biopharmaceutical company’s stock worth $953,000 after acquiring an additional 143 shares in the last quarter. Finally, Public Employees Retirement System of Ohio boosted its position in shares of Incyte by 1.8% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 102,995 shares of the biopharmaceutical company’s stock worth $12,968,000 after acquiring an additional 1,809 shares in the last quarter. 90.02% of the stock is owned by institutional investors and hedge funds.
Incyte Co. (NASDAQ INCY) opened at $88.03 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82. Incyte Co. has a 52-week low of $80.85 and a 52-week high of $153.15. The stock has a market capitalization of $18,580.00, a P/E ratio of -110.04 and a beta of 0.59.
INCY has been the subject of several research reports. Deutsche Bank initiated coverage on Incyte in a report on Tuesday, December 12th. They issued a “hold” rating and a $106.00 target price for the company. Zacks Investment Research downgraded Incyte from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Oppenheimer reissued a “hold” rating and issued a $110.00 target price (down from $120.00) on shares of Incyte in a report on Monday, January 22nd. BMO Capital Markets reduced their target price on Incyte from $163.00 to $162.00 and set an “outperform” rating for the company in a report on Thursday, October 26th. Finally, Citigroup reissued a “market perform” rating and issued a $120.00 target price (down from $135.00) on shares of Incyte in a report on Tuesday, January 2nd. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Incyte presently has a consensus rating of “Buy” and an average price target of $143.25.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.